Your LDL is 120 mg/dL. Your ApoB is within range. Your HDL is on the lower end but acceptable. And your Lp(a) is 150 nmol/L, which means your cardiovascular risk is significantly higher than your standard lipid panel suggests. The catch? You have probably never tested Lp(a), and neither has whoever manages your bloodwork.
The clinical reality is that Lp(a) testing is cheap, around $50 to $100 out of pocket, and requires no special preparation. You can add it to any standard lipid panel. The problem is that most licensed medical professionals do not order it unless you ask. If you are an AAS user, you should not wait for a licensed medical professional to suggest it. Bring it up yourself. A single test at any point in your life gives you a permanent risk marker, because your Lp(a) level will not change with age, weight, or training status. That one number can shift your entire cardiovascular risk stratification, so it is worth the small cost and the five minutes of extra blood draw.
What Is Lp(a)?
Lipoprotein(a), pronounced "L-p-little-a", is an LDL-like particle with one critical difference: it carries an additional protein called apolipoprotein(a) attached to its ApoB component. That apolipoprotein(a) is structurally similar to plasminogen, a key clotting protein, which gives Lp(a) its dual danger. It is both pro-atherogenic, like LDL, depositing cholesterol in artery walls, and pro-thrombotic, interfering with the body's natural clot-dissolving mechanisms.
Lp(a) is approximately 90% genetically determined, and that's the most important fact about it. Your genes set your Lp(a) level, and it remains stable throughout your life. Diet, exercise, and most medications won't change it meaningfully. So a single measurement at any point in your life establishes your risk level permanently. There's no need for annual retesting.
Because Lp(a) is so genetically fixed, a single measurement is sufficient for life. You do not need to recheck it annually like LDL or HDL. The only reason to repeat it is if you are using a therapy that might lower it, such as niacin or a PCSK9 inhibitor, to see if you are responding. Even then, the change is modest, so a repeat test after 3 to 6 months of therapy is reasonable. For everyone else, one test at any age, even in your 20s, gives you a permanent risk marker. This is why the European Atherosclerosis Society recommends testing Lp(a) once in every adult at least once in a lifetime, regardless of cardiovascular risk status.
Roughly one in five people has an Lp(a) level above 75 nmol/L, the threshold where cardiovascular risk starts to increase meaningfully. Among individuals with a family history of premature cardiovascular disease, the prevalence is even higher, with approximately 30% having elevated Lp(a). Despite this, Lp(a) is not included in standard lipid panels and requires a specific order.
Lipoprotein(a) — Lp(a)
Lp(a) and AAS: A Compounding Risk
For AAS users, Lp(a) matters more than it does for the general population, and the reason is compounding. AAS suppress HDL cholesterol and raise LDL and ApoB, the classic AAS-induced dyslipidemia pattern. If you have an elevated Lp(a) on top of this, your cardiovascular risk is not simply "LDL risk plus Lp(a) risk." The two factors interact: Lp(a) particles are themselves atherogenic, and their ApoB content adds to the total ApoB burden that drives plaque formation.
The compounding effect is not just additive; it is multiplicative. AAS use typically lowers HDL by 20 to 50% and raises LDL by 20 to 40%, depending on the compound and dose. If you already have an Lp(a) of 100 nmol/L, your ApoB particles are more atherogenic because each one carries the additional pro-thrombotic apolipoprotein(a). This means that for the same LDL level, an AAS user with high Lp(a) has a higher risk of plaque rupture and thrombotic events than a non-user with the same LDL. In practical terms, if your Lp(a) is above 75 nmol/L and you are on cycle, you should consider your LDL target to be below 70 mg/dL, not the standard 100 mg/dL.
Some evidence also points to AAS mildly raising Lp(a) in certain users, though the effect isn't consistent across studies or compounds. Oral 17-alpha-alkylated steroids tend to hit this marker harder than injectables. If you're running orals and have a family history of early heart disease, getting Lp(a) tested before and during your cycle tells you whether your specific protocol is actually moving the needle.
The practical implication: if your Lp(a) is elevated, your cardiovascular risk management strategy should be more aggressive than it would be for someone with the same LDL and HDL but normal Lp(a). This means tighter control of modifiable risk factors: blood pressure, LDL/ApoB, smoking, glucose, all to offset the fixed risk from Lp(a). It also means more careful compound selection, favoring compounds with milder lipid impact.
One common mistake is assuming that because Lp(a) is genetic, there is nothing you can do. That is false. You cannot change the Lp(a) level itself, but you can change how much it matters. The key is to keep your other risk factors as low as possible. That means maintaining blood pressure below 120/80, keeping LDL below 70 mg/dL if you have high Lp(a), and avoiding smoking entirely. For AAS users, this also means choosing compounds that are less dyslipidemic, such as injectable testosterone over oral 17-alpha-alkylated agents, and reducing the dose if your lipid panel is deteriorating — both safe moves you can make directly. A statin or ezetimibe to manage LDL more aggressively, even at a baseline LDL that wouldn't otherwise trigger treatment, is worth raising with a licensed medical professional given the elevated Lp(a) context.
Who Should Test Lp(a)
Testing and Interpretation
Lp(a) gets reported in either nmol/L, which counts particles, or mg/dL, which measures mass. The nmol/L unit is the better choice. Lp(a) particles come in different sizes, and a mass measurement can miss risk in people with large Lp(a) isoforms. The European Atherosclerosis Society recommends nmol/L whenever you have the option.
- < 30 nmol/L: Optimal. No increased risk from Lp(a).
- A result of 30-75 nmol/L sits in the borderline range. Consider rechecking once in 5-10 years to confirm stability.
- Sitting at 75-125 nmol/L puts you in the elevated zone. That's a moderate risk increase, so you'll want to manage other risk factors aggressively.
- > 125 nmol/L: High. Significant risk increase. Consider pharmacology options (PCSK9 inhibitors).
For AAS users, the threshold for concern sits lower. If your Lp(a) is above 75 nmol/L and you regularly use compounds that suppress HDL and raise ApoB, your cumulative risk profile may warrant aggressive management even at levels the general population would call "borderline.
For AAS users, the threshold for concern is lower. If your Lp(a) is above 75 nmol/L and you regularly use compounds that suppress HDL and raise ApoB, your cumulative risk profile may warrant aggressive management even at levels that would be considered borderline in the general population. For example, an Lp(a) of 60 nmol/L is often dismissed as low risk, but if you are running 500 mg of testosterone per week and your HDL drops to 25 mg/dL, that same Lp(a) becomes a significant contributor to plaque formation. In this scenario, reducing your AAS dose is a safe first move you can make directly. A PCSK9 inhibitor for elevated LDL, and a coronary artery calcium score if you're over 40, are both worth raising with a licensed medical professional or lipid specialist rather than pursuing on your own.
Management Options for Elevated Lp(a)
Lp(a) is notoriously difficult to lower. Lifestyle interventions, including diet, exercise, and weight loss, have no meaningful effect. Statins, surprisingly, do not lower Lp(a) and may even raise it slightly in some individuals. The options that do work fall into two categories: modest reductions and potent reductions.
Niacin (1-2 g/day) lowers Lp(a) by 15-30%, but its use is limited by side effects: flushing (which can be managed with aspirin taken 30 minutes before dosing), glucose elevation, and gastrointestinal discomfort. Niacin also lowers LDL and raises HDL, making it a multi-purpose option for AAS users with combined dyslipidemia and elevated Lp(a). The extended-release formulation has a better side effect profile than immediate-release.
Niacin is the only oral agent that reliably lowers Lp(a), but its use in AAS users requires caution. Niacin can raise blood glucose and may worsen insulin resistance, which is already a concern with some AAS compounds. It also causes flushing, which can be mitigated with aspirin, but the glucose effect is dose-dependent. At the gram-level doses needed for a meaningful Lp(a) effect, niacin functions more like a therapeutic intervention than a casual supplement, so working out the starting dose and titration schedule with a licensed medical professional — including baseline and follow-up fasting glucose and HbA1c — is worth it given the glucose risk. Also note that niacin's Lp(a) reduction is modest, 15 to 30%, so it will not normalize a high level. It is a tool, not a cure. For AAS users, the more important step is to address the AAS-induced dyslipidemia itself, because that is the modifiable part of the risk equation.
PCSK9 inhibitors (alirocumab, evolocumab) lower Lp(a) by 25-30% while simultaneously lowering LDL by 50-60%. They are the most effective currently available option for Lp(a) reduction, but they are expensive (approximately $5,000-7,000 per year) and require injection every 2-4 weeks. In most healthcare systems, approval requires a documented history of cardiovascular disease or familial hypercholesterolemia.